People in the News: Albert Luderer; Leroy Hood; and More

Nov 11, 2011

Premium

BioNano Genomics said this week that it has elected Albert Luderer to its board of directors.

Luderer currently serves as CEO and director of Integrated Diagnostics. He was previously president and CEO of BioTrove, now part of Life Technologies. Previously, he served as CEO of Light Sciences and president and COO of BioMérieux.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Breaking News

The Scan

This Week in PLOS

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

Things Not Found

With a new collection, PLOS highlights negative results it has published.

Is the Sequencer Half Full or Half Empty?

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

Packs a Punch

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

Featured White Papers

Reverse Phase Protein Arrays for Cell Signaling: Using the InnoScan 710-IR scanner improves sensitivity and dynamic range.

Infrared detection decreases nitrocellulose autofluorescence and improves RPPA assays signal‐to‐noise ratio over visible wavelength detection

Mar

05

Featured Webinar

Integrating Metabolomic and Proteomic Profiles for 'Less Impersonal' Medicine

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.

Main menu